NCT00620607View on ClinicalTrials.gov

huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

September 30, 2010

Conditions
Stomach NeoplasmsMetastatic or Locally Advanced Gastric CancerMetastatic or Local Advanced GE Junction Cancer
Interventions
DRUG

huC242-DM4

dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks

Trial Locations (4)

35294

UAB Comprehensive Cancer Center, Birmingham

37232

Vanderbilt-Ingram Cancer Center, Nashville

Unknown

U.T. M.D. Anderson Cancer Center, Houston

South Texas Accelerated Research Therapeutics, San Antonio

Sponsors

Lead Sponsor

ImmunoGen, Inc.
All Listed Sponsors
lead

ImmunoGen, Inc.

INDUSTRY